U.S. NeuroSurgical Holdings, Inc. Files 10-K/A Amendment

TL;DR

<b>U.S. NeuroSurgical Holdings, Inc. filed an amendment to its 2023 10-K report, detailing corporate information and stock registration.</b>

AI Summary

U.S. NeuroSurgical Holdings, Inc. (EHSI) filed a Amended Annual Report (10-K/A) with the SEC on April 24, 2024. Filing is an Amendment No. 1 to the annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and has an IRS Employer Identification No. of 47-5370333. Principal executive offices are located at 1131 W 6th Street, Ontario, CA 91672. The issuer's telephone number is (949) 249-1170. Common Stock, par value $.01 per share, is registered under Section 12(g) of the Act; no securities are registered under Section 12(b).

Why It Matters

For investors and stakeholders tracking U.S. NeuroSurgical Holdings, Inc., this filing contains several important signals. This amendment provides updated or corrected information for the annual report, which is crucial for investors to have the most accurate financial and corporate details. The filing clarifies the company's stock registration status, indicating that only common stock is registered under Section 12(g), which affects regulatory oversight and reporting requirements.

Risk Assessment

Risk Level: low — U.S. NeuroSurgical Holdings, Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, suggesting potential corrections or updates to previously filed information, but does not indicate significant new risks or operational changes.

Analyst Insight

Review the specific changes made in Amendment No. 1 to the 10-K filing to understand any updated corporate or financial disclosures.

Key Numbers

• 20231231 — Fiscal Year End (Reported fiscal year end date.)
• 20240424 — Filing Date (Date the amendment was filed.)
• 0.01 — Par Value (Par value of common stock.)

Key Players & Entities

• U.S. NeuroSurgical Holdings, Inc. (company) — Filer name and subject of the report.
• Delaware (location) — State of incorporation.
• 47-5370333 (other) — IRS Employer Identification No.
• 1131 W 6th Street, Ontario, CA 91672 (location) — Address of principal executive offices.
• (949) 249-1170 (phone) — Issuer's telephone number.
• Common Stock, par value $.01 per share (security) — Registered under Section 12(g) of the Act.

FAQ

Industry Context

The company operates within the specialty outpatient facilities sector, focusing on neurosurgical services.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring annual reports and amendments for public companies.

What Investors Should Do

1. Analyze the content of Amendment No. 1 for any substantive changes to the original 10-K.
2. Verify the accuracy of corporate details and stock registration information provided.
3. Monitor future filings for any further updates or disclosures from U.S. NeuroSurgical Holdings, Inc.

Year-Over-Year Comparison

This is an amendment (10-K/A) to the previously filed annual report for the fiscal year ended December 31, 2023.

Key Financial Figures

• $2,390,000 — e Company has an accumulated deficit of $2,390,000 and $1,710,000 as of December 31, 2023,
• $1,710,000 — n accumulated deficit of $2,390,000 and $1,710,000 as of December 31, 2023, and December 3
• $80,000 — d there is a working capital deficit of $80,000 as of December 31, 2023. These conditio

Filing Documents

• ef20027571_10ka.htm (10-K/A) — 53KB
• ef20027571_ex31-1.htm (EX-31.1) — 14KB
• ef20027571_ex32-1.htm (EX-32.1) — 5KB
• 0001140361-24-021725.txt (&nbsp;) — 258KB
• usnu-20231231.xsd (EX-101.SCH) — 4KB
• usnu-20231231_lab.xml (EX-101.LAB) — 26KB
• usnu-20231231_pre.xml (EX-101.PRE) — 19KB
• ef20027571_10ka_htm.xml (XML) — 7KB

Financial Statements and Financial Statement Schedules . None

Financial Statements and Financial Statement Schedules . None (b) Exhibits. 31.1* Certifications of CEO and CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1* Certifications of CEO and CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 * Filed herewith (c) Financial Statement Schedules . None 5

SIGNATURES

SIGNATURES In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. U.S. NeuroSurgical Holdings, Inc. (Registrant) By /s/ Alan Gold Alan Gold President & Chairman of the Board and Principal Financial Officer Dated: April 24, 2024 In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. April 24, 2024 /s/ Alan Gold Alan Gold President & Chairman of the Board April 24, 2024 /s/ William F. Leimkuhler William F. Leimkuhler Director April 24, 2024 /s/ Charles H. Merriman III Charles H. Merriman III Director April 24, 2024 /s/ William St. Lawrence William St. Lawrence Director 6

View Full Filing

View this 10-K/A filing on SEC EDGAR